C W Serby
Overview
Explore the profile of C W Serby including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
401
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Casaburi R, Mahler D, Jones P, Wanner A, San P, ZuWallack R, et al.
Eur Respir J
. 2002 Feb;
19(2):217-24.
PMID: 11866001
Currently available inhaled bronchodilators used as therapy for chronic obstructive pulmonary disease (COPD) necessitate multiple daily dosing. The present study evaluates the long-term safety and efficacy of tiotropium, a new...
2.
CHODOSH S, Flanders J, Kesten S, Serby C, Hochrainer D, Witek Jr T
J Aerosol Med
. 2001 Nov;
14(3):309-15.
PMID: 11693842
The HandiHaler is a dry powder breath activated inhaler system developed for inhalation therapy for patients with airway disease. Its operation is based on the evacuation of powder from a...
3.
Casaburi R, Briggs Jr D, Donohue J, Serby C, Menjoge S, Witek Jr T
Chest
. 2000 Nov;
118(5):1294-302.
PMID: 11083677
Study Objective: To compare the bronchodilator efficacy and safety of tiotropium and placebo. Design: A 3-month, randomized, double-blind, placebo-controlled, multicenter trial. Setting: Outpatient. Patients: Four hundred seventy patients with stable...
4.
Littner M, Ilowite J, Tashkin D, Friedman M, Serby C, Menjoge S, et al.
Am J Respir Crit Care Med
. 2000 Apr;
161(4 Pt 1):1136-42.
PMID: 10764302
Tiotropium (Spiriva; Ba679BR) is a new-generation, long-acting anticholinergic bronchodilator that has muscarinic M(1) and M(3) receptor subtype selectivity. A multicenter, randomized, double-blind, parallel group, placebo-controlled study was conducted to evaluate...
5.
Dorinsky P, Reisner C, Ferguson G, Menjoge S, Serby C, Witek Jr T
Chest
. 1999 Apr;
115(4):966-71.
PMID: 10208193
Study Objectives: To determine whether the combination of ipratropium bromide and albuterol results in greater and more consistent pulmonary function test (PFT) response rates than ipratropium bromide or albuterol alone...
6.
Friedman M, Serby C, Menjoge S, Wilson J, Hilleman D, Witek Jr T
Chest
. 1999 Mar;
115(3):635-41.
PMID: 10084468
Study Objective: To conduct a post hoc pharmacoeconomic evaluation of two double-blind, randomized, prospective, parallel group studies comparing the long-term efficacy and safety of ipratropium combined with albuterol in a...
7.
Rennard S, Serby C, Ghafouri M, Johnson P, Friedman M
Chest
. 1996 Jul;
110(1):62-70.
PMID: 8681667
Objective: Bronchodilators are routinely used in the long-term therapy of patients with COPD. These drugs are generally evaluated for their short-term bronchodilatory effects. Long-term and short-term benefits, however, are not...
8.
Konig P, Hordvik N, Serby C
Chest
. 1984 Apr;
85(4):462-4.
PMID: 6368141
The effectiveness of inhaled fenoterol doses of 0.4 mg and 0.8 mg in preventing exercise-induced asthma was investigated in 12 patients. Exercise-induced asthma was prevented by both doses for two...
9.
Konig P, Eggleston P, Serby C
Clin Allergy
. 1981 Nov;
11(6):597-604.
PMID: 7333003
The effectiveness of inhaled versus oral metaproterenol in preventing exercise-induced asthma (EIA) was studied. Inhaled metaproterenol given 10 min before the exercise significantly reduced the degree of EIA in a...